$VTAK
Catheter Precision, Inc.

2021 Q1 Form 10-K Financial Statement

#000156459021013653 Filed on March 17, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4 2020
Revenue $1.118M $0.00 $4.405M
YoY Change -18.63% -100.0% -38.81%
Cost Of Revenue $1.373M $426.0K $5.482M
YoY Change -13.32% -75.66% -38.06%
Gross Profit -$255.0K -$426.0K -$1.077M
YoY Change 21.43% 18.33% -34.77%
Gross Profit Margin -22.81% -24.45%
Selling, General & Admin $4.114M $6.379M $25.97M
YoY Change -34.54% -26.19% -49.61%
% of Gross Profit
Research & Development $2.816M $3.421M $9.008M
YoY Change 117.45% 308.23% 98.85%
% of Gross Profit
Depreciation & Amortization $400.0K $520.0K $1.600M
YoY Change -20.0% 39.04% 12.68%
% of Gross Profit
Operating Expenses $6.930M $9.800M $34.98M
YoY Change -8.58% 3.38% -37.62%
Operating Profit -$7.185M -$10.23M -$36.06M
YoY Change -7.77% 3.92% -37.54%
Interest Expense $52.00K $108.0K
YoY Change 108.0% -56.8%
% of Operating Profit
Other Income/Expense, Net -$51.00K -$9.000K $88.00K
YoY Change -157.3% -88.83%
Pretax Income -$6.877M -$10.24M -$35.31M
YoY Change -10.7% 5.13% -37.98%
Income Tax $0.00 $7.000K $7.000K
% Of Pretax Income
Net Earnings -$7.236M -$10.44M -$36.05M
YoY Change -6.04% 7.19% -36.72%
Net Earnings / Revenue -647.23% -818.27%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.481M -$3.599M -$21.22M
COMMON SHARES
Basic Shares Outstanding 3.259M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.95M $23.91M $23.91M
YoY Change -31.94% -21.82% -21.82%
Cash & Equivalents $15.95M $23.91M $23.91M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $1.555M $1.258M $2.813M
YoY Change -13.23% -32.37% -28.02%
Inventory $2.249M $877.0K $877.0K
Prepaid Expenses
Receivables $160.0K $24.00K $24.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $19.92M $27.62M $27.62M
YoY Change -30.57% -23.28% -23.28%
LONG-TERM ASSETS
Property, Plant & Equipment $5.213M $2.527M $5.011M
YoY Change -29.9% -49.96% -28.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $131.0K $45.00K $807.0K
YoY Change -25.14% -77.04% -26.77%
Total Long-Term Assets $5.344M $5.818M $5.818M
YoY Change -29.79% -28.0% -28.0%
TOTAL ASSETS
Total Short-Term Assets $19.92M $27.62M $27.62M
Total Long-Term Assets $5.344M $5.818M $5.818M
Total Assets $25.26M $33.44M $33.44M
YoY Change -30.41% -24.14% -24.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $977.0K $471.0K $471.0K
YoY Change -27.95% -69.26% -61.39%
Accrued Expenses $2.551M $4.147M $4.503M
YoY Change 5.89% 56.96% 68.15%
Deferred Revenue $1.801M
YoY Change -11.24%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $674.0K $686.0K $686.0K
YoY Change 130.03% 134.13% 134.13%
Total Short-Term Liabilities $5.979M $7.762M $7.762M
YoY Change -0.71% 13.91% 13.91%
LONG-TERM LIABILITIES
Long-Term Debt $1.326M $1.579M $1.579M
YoY Change 601.59% 495.85% 495.85%
Other Long-Term Liabilities $2.812M $2.950M $2.950M
YoY Change -22.21% -23.42% -23.42%
Total Long-Term Liabilities $4.138M $4.529M $4.529M
YoY Change 8.78% 10.01% 10.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.979M $7.762M $7.762M
Total Long-Term Liabilities $4.138M $4.529M $4.529M
Total Liabilities $10.12M $12.29M $12.29M
YoY Change 2.96% 12.44% 12.44%
SHAREHOLDERS EQUITY
Retained Earnings -$160.4M -$153.2M
YoY Change 30.77%
Common Stock $175.6M $174.3M
YoY Change 16.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.15M $21.15M $21.15M
YoY Change
Total Liabilities & Shareholders Equity $25.26M $33.44M $33.44M
YoY Change -30.41% -24.14% -24.14%

Cashflow Statement

Concept 2021 Q1 2020 Q4 2020
OPERATING ACTIVITIES
Net Income -$7.236M -$10.44M -$36.05M
YoY Change -6.04% 7.19% -36.72%
Depreciation, Depletion And Amortization $400.0K $520.0K $1.600M
YoY Change -20.0% 39.04% 12.68%
Cash From Operating Activities -$8.078M -$9.414M -$28.30M
YoY Change 14.7% -1.65% -14.68%
INVESTING ACTIVITIES
Capital Expenditures $20.00K $5.000K $67.00K
YoY Change -28.57% -110.42% -75.0%
Acquisitions
YoY Change
Other Investing Activities $309.0K $0.00 $16.00M
YoY Change -97.19% -100.0% -201.5%
Cash From Investing Activities $289.0K $5.000K $15.93M
YoY Change -97.37% -99.95% -199.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -163.0K -331.0K 21.69M
YoY Change 114.47% 7.47% -4224.14%
NET CHANGE
Cash From Operating Activities -8.078M -9.414M -28.30M
Cash From Investing Activities 289.0K 5.000K 15.93M
Cash From Financing Activities -163.0K -331.0K 21.69M
Net Change In Cash -7.952M -9.740M 9.322M
YoY Change -306.38% -13627.78% -118.74%
FREE CASH FLOW
Cash From Operating Activities -$8.078M -$9.414M -$28.30M
Capital Expenditures $20.00K $5.000K $67.00K
Free Cash Flow -$8.098M -$9.419M -$28.37M
YoY Change 14.52% -1.1% -15.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2835000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
196000
CY2019Q4 us-gaap Assets
Assets
44081000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1532000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2642000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2029000
CY2019Q4 rmed Equipment Financing Obligations Current
EquipmentFinancingObligationsCurrent
293000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
421000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7762000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6814000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
686000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2264000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7199000
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8850000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-21.22
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1699000
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
526000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-251000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2185000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
338000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
407000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-184000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
417000
CY2019 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-283000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33173000
CY2019 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
20697000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
67000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15933000
CY2020 rmed Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
19887000
CY2020 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2000000
CY2019 us-gaap Profit Loss
ProfitLoss
-56957000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
268000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16032000
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
42000
CY2019 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
37000
CY2020 rmed Payments On Equipment Financing
PaymentsOnEquipmentFinancing
293000
CY2020 us-gaap Gross Profit
GrossProfit
-1077000
CY2019 us-gaap Gross Profit
GrossProfit
-1651000
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5482000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23906000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4348000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1801000
CY2020Q4 rmed Equipment Financing Obligations Current
EquipmentFinancingObligationsCurrent
265000
CY2019 rmed Transfer From Inventories To Property And Equipment For Demonstration Lasers Lasers And Lasers Placed With Customers
TransferFromInventoriesToPropertyAndEquipmentForDemonstrationLasersLasersAndLasersPlacedWithCustomers
1505000
CY2019Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
15993000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
786000
CY2020Q4 us-gaap Inventory Net
InventoryNet
2218000
CY2019Q4 us-gaap Inventory Net
InventoryNet
2777000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1258000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
27620000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3211000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
123000
CY2020Q4 us-gaap Assets
Assets
33438000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
571000
CY2020 rmed Transfer From Inventories To Property And Equipment For Demonstration Lasers Lasers And Lasers Placed With Customers
TransferFromInventoriesToPropertyAndEquipmentForDemonstrationLasersLasersAndLasersPlacedWithCustomers
207000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
28000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
49000
CY2019 us-gaap Income Taxes Paid
IncomeTaxesPaid
30000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
500000
CY2019 rmed Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
300000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
432000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
445000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
459000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
472000
CY2019 rmed Payments On Equipment Financing
PaymentsOnEquipmentFinancing
338000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21693000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-526000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9322000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-49731000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14584000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64315000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
356000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
318000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2620000
CY2019Q4 us-gaap Liabilities
Liabilities
10931000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
150280000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117157000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
21147000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
33150000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
33438000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44081000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3188679
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
550814
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3188679
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
550814
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4405000
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
25974000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9008000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1232000
CY2020Q4 rmed Long Term Portion Of Promissory Notes
LongTermPortionOfPromissoryNotes
1579000
CY2019Q4 rmed Equipment Financing Obligations Noncurrent
EquipmentFinancingObligationsNoncurrent
265000
CY2020Q4 us-gaap Liabilities
Liabilities
12291000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
174342000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-153202000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
26000
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
51549000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4530000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
129000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
1038000
CY2020 us-gaap Interest Expense
InterestExpense
108000
CY2019 us-gaap Interest Expense
InterestExpense
250000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
21000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
788000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-36045000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-56957000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-108.28
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-26000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
26000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-26000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
26000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36071000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-56931000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
66726000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-188000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23543000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11625000
CY2020 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
7492000
CY2020 rmed Exercise Of Warrants
ExerciseOfWarrants
827000
CY2020 rmed Common Stock Issued Pursuant To The Vesting Of Restricted Stock Units And Espp
CommonStockIssuedPursuantToTheVestingOfRestrictedStockUnitsAndESPP
42000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4082000
CY2020 us-gaap Profit Loss
ProfitLoss
-36045000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2365000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1750000
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
180000
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
283000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
4082000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
23543000
CY2020 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-99000
CY2019 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-123000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-368000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-352000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-642000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-961000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1706000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-774000
CY2020 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-318000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28304000
CY2019 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
36461000
CY2020 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
16000000
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
827000
CY2020 rmed Payments Of Offering Costs Related To Issuance Of Common Stock And Warrants
PaymentsOfOfferingCostsRelatedToIssuanceOfCommonStockAndWarrants
770000
CY2020Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
200000
CY2019Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
400000
CY2020 us-gaap Operating Leases Income Statement Lease Revenue
OperatingLeasesIncomeStatementLeaseRevenue
600000
CY2019 rmed Payments For Restricted Stock Tax Liability On Settlement
PaymentsForRestrictedStockTaxLiabilityOnSettlement
225000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23906000
CY2020 rmed Payment For Underwriters Discount
PaymentForUnderwritersDiscount
2113000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">Use of estimates<font style="font-weight:normal;font-style:normal;">&#8212;The </font><font style="color:#000000;font-weight:normal;font-style:normal;">financial statements of the Company have been prepared by management in accordance with accounting principles generally accepted in the United States of America. The</font><font style="font-weight:normal;font-style:normal;"> preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and reported disclosures of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. The Company&#8217;s financial statements are based upon a number of estimates, including but not limited to, allowance for doubtful accounts, reserves for warranty costs including product recalls, evaluation of probable loss contingencies, fair value of stock option awards granted and revenue recognition for multiple performance obligations.</font></p>
CY2019 us-gaap Operating Leases Income Statement Lease Revenue
OperatingLeasesIncomeStatementLeaseRevenue
700000
CY2020 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement.
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
15967000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
26000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
15993000
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1739000
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of credit risk<font style="font-weight:normal;font-style:normal;">&#8212;Credit risk represents the accounting loss that would be recognized at the reporting date if counterparties failed completely to perform as contracted. Concentrations of credit risk that arise from financial instruments exist for groups of customers or counterparties when they have similar economic characteristics that would cause their ability to meet contractual obligations to be similarly affected by changes in economic or other conditions described below. </font></p> <p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist of cash, cash equivalents and short-term investments balances maintained in excess of Federal Depository Insurance Corporation limits, and accounts receivable which have no collateral or security. The Company monitors the financial condition of the banks in which it currently has deposits. The Company has not experienced any significant losses in this respect and believes that it is not exposed to any significant related risk. </p> <p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exposure to losses on accounts receivable is dependent on the individual customer&#8217;s financial condition. The Company monitors its exposure to credit losses and reserves for those accounts receivable that it deems to be not collectible. </p> <p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No individual customer represented greater than 10% of total net revenue for the years ended December&#160;31, 2020 and 2019. One individual customer represented 10% of accounts receivable for each of the years ended December 31, 2020 and 2019, respectively. <font style="font-size:12pt;">&#160;</font> <font style="font-size:12pt;">&#160;</font>&#160; </p>
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2300000
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
270000
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
215000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
209000
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
262000
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000
CY2020 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
In November 2020, the board of directors approved a Reverse Stock Split ratio of 1-for-25
CY2020 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2900000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73000000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2900000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
355000
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
214000
CY2020 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
264000
CY2019 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
142000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
271000
CY2020Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3300000
CY2019Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2800000
CY2020 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2000000
CY2019 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1900000
CY2020 rmed Revenue Remaining Service Period To Recognize Deferred Revenue
RevenueRemainingServicePeriodToRecognizeDeferredRevenue
2024
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2109000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2602000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1163000
CY2020Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
242000
CY2019Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
338000
CY2020Q4 rmed Accrued Services Current
AccruedServicesCurrent
1504000
CY2019Q4 rmed Accrued Services Current
AccruedServicesCurrent
1141000
CY2018Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
112000
CY2020 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
87000
CY2019 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
889000
CY2020 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
-2000
CY2019 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
-28000
CY2020 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
181000
CY2019 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
635000
CY2020 us-gaap Product Warranty Expense
ProductWarrantyExpense
100000
CY2019 us-gaap Product Warranty Expense
ProductWarrantyExpense
900000
CY2020 rmed Operating Lease Number Of Leases
OperatingLeaseNumberOfLeases
2
CY2020Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.07
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
500000
CY2020 rmed Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
400000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
528000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
987000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3323000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
703000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2620000
CY2020 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
0
CY2020Q2 rmed Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
73506
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3749000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21929000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P1Y2M12D
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.051
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.019
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.004
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.022
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.095
CY2020 rmed Effective Income Tax Rate Reconciliation Deferred Tax Adjustments
EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustments
0.570
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.332
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.130
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
7000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
15000
CY2020 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
7000
CY2019 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
15000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3720000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16096000
CY2020Q4 rmed Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
691000
CY2019Q4 rmed Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
766000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
101000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
61000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
448000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
299000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
301000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
642000
CY2019Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
850000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
32000
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
253000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4910000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4821000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10843000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23148000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
805000
CY2019Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1026000
CY2020Q4 rmed Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
655000
CY2019Q4 rmed Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
739000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
61000
CY2019Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
92000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1521000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1857000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9322000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
21291000
CY2020 rmed Operating Loss Carryforwards Expiration Year
OperatingLossCarryforwardsExpirationYear
2032
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
20800000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020 rmed Income Tax Examination Years Under Examination
IncomeTaxExaminationYearsUnderExamination
2016 and later
CY2020 rmed Audit Committee Findings Description
AuditCommitteeFindingsDescription
The primary investigative findings were: (i) the DABRA catheter frequently failed to calibrate and occasionally overheated, posing a risk of injury to physicians and patients; (ii) the Company’s explanations regarding its fourth quarter 2018 and first quarter 2019 sales created a risk of confusion because they did not explicitly reference inconsistent DABRA catheter performance and catheter failures; (iii) the Company failed to timely make at least two Medical Device Reports, or MDRs, to the FDA; (iv) the Company, out of a concern for the DABRA catheters’ performance, engaged in systematic efforts to replace product held by customers, which constituted product recalls, but were not documented as such, (v) the Company lack documentation of sufficient detail and specificity to support certain payments to physicians, ostensibly for training and consulting services, and as to three physicians did not accurately reflect the purpose and nature of approximately $300,000 of payments, which could be perceived as an improper attempt to obtain business or to gain special advantage, (vi) while the indication for use in the 510(k) clearance the Company obtained for the DABRA system is not for atherectomy, the Company’s salespeople were instructed to characterize DABRA as performing atherectomy and to encourage doctors to seek reimbursement using atherectomy codes, (vii) the Company’s determinations to direct potentially valuable benefits and opportunities to doctors were informed in part by sales prospects, and (viii) the Company received complaints regarding regulatory or compliance concerns that, because they implicated executive officers, should have been brought to the attention of the Board or the Audit Committee, but were not.
CY2020 rmed Payments That Lack Documentation Of Sufficent Detail
PaymentsThatLackDocumentationOfSufficentDetail
300000
CY2020Q4 us-gaap Loss Contingency Accrual Payments
LossContingencyAccrualPayments
2700000
CY2020Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
300000
CY2020 us-gaap General Discussion Of Pension And Other Postretirement Benefits
GeneralDiscussionOfPensionAndOtherPostretirementBenefits
In January 2019, the Company established a defined contribution plan under Section 401(k) of the Internal Revenue Code (“401(k) Plan”) that the Company administers for participating employees’ contributions.
CY2020 us-gaap Description Of Defined Contribution Pension And Other Postretirement Plans
DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans
All full-time employees are eligible under the 401(k) Plan. The Company will make contributions, based on a match of 100% of each employee’s contribution up to 3% and 50% of contributions between 3% and 5%, with the match-eligible contribution being limited to 4% of the employee’s eligible compensation.
CY2019 us-gaap Defined Contribution Plan Administrative Expenses
DefinedContributionPlanAdministrativeExpenses
300000
CY2020 us-gaap Defined Contribution Plan Administrative Expenses
DefinedContributionPlanAdministrativeExpenses
300000
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2020 us-gaap Revenues
Revenues
4405000
CY2019 us-gaap Revenues
Revenues
7199000
CY2020 us-gaap Cost Of Revenue
CostOfRevenue
5482000
CY2019 us-gaap Cost Of Revenue
CostOfRevenue
8850000

Files In Submission

Name View Source Status
0001564590-21-013653-index-headers.html Edgar Link pending
0001564590-21-013653-index.html Edgar Link pending
0001564590-21-013653.txt Edgar Link pending
0001564590-21-013653-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gmu5uaxbhb4n000001.jpg Edgar Link pending
gmu5uaxbhb4n000002.jpg Edgar Link pending
gmu5uaxbhb4n000003.jpg Edgar Link pending
gmu5uaxbhb4n000004.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rmed-10k_20201231.htm Edgar Link pending
rmed-20201231.xml Edgar Link completed
rmed-20201231.xsd Edgar Link pending
rmed-20201231_cal.xml Edgar Link unprocessable
rmed-20201231_def.xml Edgar Link unprocessable
rmed-20201231_lab.xml Edgar Link unprocessable
rmed-20201231_pre.xml Edgar Link unprocessable
rmed-ex1019_96.htm Edgar Link pending
rmed-ex1020_97.htm Edgar Link pending
rmed-ex231_9.htm Edgar Link pending
rmed-ex311_6.htm Edgar Link pending
rmed-ex312_99.htm Edgar Link pending
rmed-ex321_7.htm Edgar Link pending
rmed-ex322_98.htm Edgar Link pending
rmed-ex42_8.htm Edgar Link pending
Show.js Edgar Link pending